Insider Selling: PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Insider Sells $134,400.00 in Stock

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) insider Leila Alland sold 4,000 shares of PMV Pharmaceuticals stock in a transaction that occurred on Monday, June 7th. The shares were sold at an average price of $33.60, for a total transaction of $134,400.00. Following the sale, the insider now owns 4,000 shares in the company, valued at approximately $134,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Leila Alland also recently made the following trade(s):

  • On Friday, May 7th, Leila Alland sold 4,000 shares of PMV Pharmaceuticals stock. The shares were sold at an average price of $34.83, for a total transaction of $139,320.00.
  • On Wednesday, April 7th, Leila Alland sold 4,000 shares of PMV Pharmaceuticals stock. The shares were sold at an average price of $33.86, for a total transaction of $135,440.00.

PMV Pharmaceuticals stock opened at $32.73 on Friday. The firm’s 50 day moving average is $33.44. PMV Pharmaceuticals, Inc. has a 1 year low of $26.38 and a 1 year high of $63.22. The company has a market capitalization of $1.47 billion and a PE ratio of -13.64.

PMV Pharmaceuticals (NASDAQ:PMVP) last announced its quarterly earnings results on Friday, May 14th. The company reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26). Sell-side analysts expect that PMV Pharmaceuticals, Inc. will post -1.22 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Avoro Capital Advisors LLC increased its position in PMV Pharmaceuticals by 27.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,350,267 shares of the company’s stock worth $130,536,000 after purchasing an additional 500,267 shares during the last quarter. BlackRock Inc. increased its position in PMV Pharmaceuticals by 6.0% in the first quarter. BlackRock Inc. now owns 1,425,873 shares of the company’s stock worth $46,897,000 after purchasing an additional 80,858 shares during the last quarter. JPMorgan Chase & Co. increased its position in PMV Pharmaceuticals by 2,421.3% in the first quarter. JPMorgan Chase & Co. now owns 935,390 shares of the company’s stock worth $30,765,000 after purchasing an additional 898,291 shares during the last quarter. Personal CFO Solutions LLC bought a new stake in PMV Pharmaceuticals in the first quarter worth $28,111,000. Finally, Victory Capital Management Inc. increased its position in PMV Pharmaceuticals by 21.9% in the first quarter. Victory Capital Management Inc. now owns 799,001 shares of the company’s stock worth $26,279,000 after purchasing an additional 143,292 shares during the last quarter. Institutional investors own 88.63% of the company’s stock.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function.

Recommended Story: volatile stocks

Insider Buying and Selling by Quarter for PMV Pharmaceuticals (NASDAQ:PMVP)

Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.